ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO270

Orai1 Mediated Ca+2 Signaling Influences IL-17 Expression in CD4+ T Cells Following I/R

Session Information

Category: Acute Kidney Injury

  • 001 AKI: Basic


  • Mehrotra, Purvi, Indiana School of Medicine, Indianapolis, Indiana, United States
  • Basile, David P., Indiana University School of Medicine, Indianapolis, Indiana, United States

T-helper 17 (Th17) cells have been implicated in the pathogenesis of acute kidney Injury (AKI). Renal Th17 cells transiently increase for up to 3-days post ischemia/reperfusion (I/R) and return to basal levels within a week. Exposure of post AKI rats to elevated dietary salt (4%) stimulates sustained induction of renal Th17 cells, which is associated with CKD progression. The store-operated calcium channel (SOCC), Orai-1 plays a role in models of inflammatory disease such as colitis or autoimmune encephalopathy, which may be influenced by dietary salt. We hypothesized that AKI primes CD4+ T cells to increase IL17 expression secondary to Orai1 dependent Ca2+ signaling.


FACs analysis demonstrated increased Orai1 protein in renal CD4+ T-cells 7 days following I/R (MFI:221644±3567) relative to sham operated controls (MFI:106924±467; p<0.05). To evaluate the role of Orai1 mediated Ca2+ influx in the progression of AKI, rats were subjected to bilateral I/R and the dependency of AKI primed T cells on Ca2+ entry was evaluated using an in vitro assay of renal CD4+ cells, which resulted in ~5 fold increase in IL17 expression in response to Ang II (10-7M) and elevated extracellular Na+ (170 mM).


The IL17 induction of AKI primed CD4+ cells in vitro was attenuated by > 95% (p<0.05) by 3 inhibitors that target Orai-1 (2-ABP (20mm), AnCoA4 (50mm) or YM58483 (120nm)). A significant percentage (40-50%) of AKI-primed CD4+ cells, but not sham-derived CD4 cells, manifested increased intracellular Ca2+ in response AngII+170 mM Na+, a response that was completely abrogated by co-incubation with AnCoA4. Furthermore, treatment with YM58483 in vivo (1mg/Kg), reduced renal Th17 cells 2 days post I/R compared to vehicle treated rats (15,3076±1265 vs 7390±439 cells/gram of kidney; p<0.05). Interestingly, YM58483 had no effect on renal Th1 or Th2 cells. In addition, YM58483 significantly reduced the extent of renal injury by attenuating the increase in serum creatinine by ~66% (p<0.05) vs vehicle treated post AKI rats.


Taken together, these data suggest that I/R leads to increased Orai-1 mediated Ca2+ influx thereby enhancing IL-17 expression and may influence the severity of AKI.


  • NIDDK Support